flanders.bio is a dynamic, member driven organisation with currently more than 350 members from Belgium and abroad. We help our members to create value by organising Networking and Training Activities, supporting Internationalisation, providing Services and building Expertise. flanders.bio and its members want to be the proud advocates of a reputable global-impact ecosystem in life sciences.
News from flanders.bio and its members
ABL acquisition extends Ardena’s early-phase offering
Early-phase contract development and manufacturing organisation (CDMO), Ardena, has acquired bioanalytical contract laboratory, Analytical Biochemical Laboratory (ABL). The acquisition of Netherlands-based ABL follows the merging of Pharmavize and Crystallics to form Ardena and broadens the CDMO’s pre-clinical and clinical offering to include bioanalytical and drug discovery services.
R-Biopharm AG & UgenTec partner to develop software for automated PCR analysis
R-Biopharm AG announced today it has entered into an agreement with UgenTec to collaborate on developing an interpretation software for R-Biopharm’s clinical PCR (Polymerase Chain Reaction) kits.
Biocartis Group NV: Disclosure of a transparency notification
Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market (the 'Belgian Transparency Act'), that it received a transparency notification dated 19 September 2017 (the 'Notification'), indicating that as a result of the acquisition of voting securities on 19 September 2017, Capfi Delen Asset Management NV now holds 5.01% of the voting rights in Biocartis. As a result, it has crossed the notification threshold of 5%.